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Abstract: Background: The use of resveratrol as a dietary supplement is limited because it is easily
oxidized and, after oral ingestion, it is metabolized into enterocytes and hepatocytes. Thus, new
formulations are needed in order to improve its oral bioavailability. Objective: The objective of
this study was to develop and characterize a gastro-resistant formulation of resveratrol for oral
administration as a dietary supplement. Method: Resveratrol was encapsulated in Eudragit-coated
pectin-alginate microparticles. Results: The microparticle size was about 1450 µm, with an
encapsulation efficiency of 41.72% ± 1.92%. The dissolution assay conducted, as specified in the
European Pharmacopoeia for delayed-release dosage forms, revealed that our microparticles were
gastro-resistant, because the resveratrol percentage released from microparticles in acid medium was
less than 10%. In addition, the high-performance liquid chromatographic (HPLC) method developed
for resveratrol content quantification in the microparticles was validated according to International
Council for Harmonisation (ICH) Q2 (R1) guidelines. Finally, the biological activity of resveratrol was
investigated in 3T3-L1 mature adipocytes, concluding that the encapsulation process does not affect
the activity of resveratrol. Conclusion: In summary, the gastro-resistant microparticles developed
could represent a suitable method of including resveratrol in dietary supplements and in functional
foods used in obesity therapy.
Keywords: resveratrol; dietary supplement; gastro-resistant; microparticles; obesity; HPLC
1. Introduction
Resveratrol (3,5,4’-trihydroxystilbene), a polyphenolic phytoalexin, is naturally produced in the
fruits of several plant species such as grapes, mulberries, and peanuts in response to exogenous stress
factors such as injuries, fungal infections, or UV irradiation [1]. It was first found in 1940 in the roots
of white hellebore (Veratrum grandiflorum). Later, in 1963, it was isolated from the roots of Polygonum
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cuspidatum, a plant used in traditional Chinese medicine. Nowadays, it is mainly extracted from red
grapes, whose fresh skin is estimated to contain about 50−100 µg of resveratrol per gram.
This polyphenol is a stilbene derivate, which exists in cis- and in trans- stereoisomeric forms
(Figure 1). The most common form in nature, the trans form, is relatively stable, but it can undergo
isomerisation to the cis- form when exposed to ultraviolet irradiation [2]. This isomerisation is not
desirable, because the trans- form is the steric form, which is responsible for the beneficial effects of
this compound. Therefore, it is important to maintain its stability in order to retain its biological and
pharmacological activities [1].
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The pharmacological activity of resveratrol takes the form of an antioxidant and anti-inflammatory
effect on a wide range of disorders associated with inflammation, such as diabetes mellitus, obesity,
cardiovascular disease, neurodegenerative diseases, or cancer [2]. Currently, resveratrol is mainly
used as an antioxidant dietary supplement to protect against cardiovascular problems and some
alterations associated with aging, and as a supplement in the treatment of cancer, obesity, diabetes, or
hypercholesterolemia [3]. The doses of resveratrol used in these supplements range from 50 to 500 mg
per capsule.
Nevertheless, the use of resveratrol is limited by its being easily oxidable and extremely
photosensitive. In addition, its low solubility in water and its rapid metabolism in enterocytes and
hepatocytes (where sulphate and glucuronic conjugates are produced), as well as its rapid elimination,
make the oral resveratrol bioavailability very low [4,5]. As a result, several strategies are being carried
out to increase its bioavailability, such as gastro-resistant microparticles that delay release until it
reaches the distal portions of the intestinal tract [6].
Microencapsulation consists of coating drugs with different materials to obtain particles of
micrometric size. It is a commonly used technique in pharmaceutical, cosmetic, and food industries,
because it increases the stability of the active component and the release of the drug is controlled [1].
In this context, pectin (a natural polysaccharide) may be considered as a suitable substance
for the development of gastro-resistant microparticles, as it is specifically degraded by pectinolytic
enzymes produced by colonic microbiota, while resisting enzymes present in the stomach and intestine.
This natural polysaccharide is composed of partially methoxylated poly (1-4-α-D-galacturonic acids)
with some 1–2 linked L-rhamnose groups [7]. It is present in the cell wall of most edible plants, and so
it is approved for its use as an excipient in oral formulations [8]. Moreover, pectins with low levels of
methoxylation can be cross-linked with calcium ions (Ca2+, divalent cations) to produce Ca-pectinate
networks, therefore, these have been used as vehicles for drug delivery [9].
In addition to pectin, alginate has also been used for the development of microparticles because
of its bio/mucoadhesive properties. Thus, the preparation of ca-pectinate/alginate microparticles is
an interesting approach, because pectin can protect from enzymatic digestion and alginate can prolong
the residence time of particles in the administration site, and so achieve controlled drug release [10].
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However, the use of pectin and alginate as the sole components of microparticles is not enough to
completely avoid resveratrol release until it reaches the distal intestinal tract. For this reason, in order
to obtain gastro-resistant microparticles, they were coated with Eudragit® FS-30D, a methacrylic acid
copolymer that dissolves at pH 7. This polymer avoids the dissolution of the microparticles in the
first portions of the gastrointestinal tract, and the consequent release of the drug in the portions of the
intestine with a pH ≥ 7 [11].
With these considerations in mind, the objective of this study was to develop and characterize
resveratrol loaded pectin/alginate blend gastro-resistant microparticles to be orally administered as a
dietary supplement.
2. Results
2.1. Validation of the Quantification Technique of Resveratrol by High-Performance Liquid Chromatographic
(HPLC)
Following ICH Q2(R1) guidelines, we have demonstrated that our method meets the linearity
criteria described in Table 1. The results show an excellent correlation between the areas of the
chromatographic peak and the concentration of the analyte in the concentration range of 5–60 µg/mL.
Table 1. Acceptance criteria.
Parameter Especification
Selectivity
Identification -
Resolution Rs > 1.5
Absence of interference no interferences
Linearity
Correlation coefficient r ≥ 0.999
C.V. response factors C.V. ≤ 2%
Relative error percentage ≤2%
Slope linearity test texp > ttable
Slope confidence intervals No include 0
Test of proportionality texp < ttable
Intercept confidence intervals Include 0
Repeatability of Instrumental System C.V. C.V. < 1.37%
Repeatability of the Method C.V. C.V. < 1.94%
Intermediate Precision
C.V. individuals C.V. < 1.94%
C.V. intermediate C.V. < 3.88%
Recovery percentage
Recovery 98.0–102.0%
Relative error percentage ≤2%
Test for equality of variances Gexp < Gtable
Robustness
Influence of analyst C.V. C.V. < 3.88%
Influence of analysis temperature C.V. C.V. < 1.94%
Stability Standard Concentration in relation to time
0
98.0–102.0%Sample
C.V.: Coefficient of variation; Gexp: Experimental G value; Gtable: G value in tables.
We also demonstrated that our method was selective, precise, accurate, and specific because all
parameters met the established acceptance criteria (Table 1).
In addition, we proved that although the resveratrol standard solution was stable for 96 h at room
temperature, the sample test solution was only stable for 24 h, taking into account the established
acceptance criteria (Table 1).
2.2. Particle Size and Morphology
After measuring the diameter of randomly selected fifty dry microparticles, as expected, the mean
particle size was 1443.45 µm ± 126.11 µm, as we expected, as a result of using the ionotropic gelation
method with a 25G needle to prepare the microparticles [9].
Molecules 2018, 23, 1886 4 of 10
In terms of morphology, the newly prepared microparticles showed a spherical and uniform
shape. However, with dehydration the morphology became more irregular, and particle size was
reduced by about 500 µm, from 2000 to 1500 µm (Figure 2).
Molecules 2018, 23, x FOR PEER REVIEW  3 of 10 
 
methacrylic acid copolymer that dissolves at pH 7. This polymer avoids the dissolution of the 
microparticles in the first portions of the gastrointestinal tract, and the consequent release of the drug 
in the portions of the intestine with a pH ≥ 7 [11]. 
With these considerations in mind, the objective of this study was to develop and characterize 
resveratrol loaded pectin/alginate blend gastro-resistant microparticles to be orally administered as 
a dietary supplement.  
2. Results 
2.1. Validation of the Quantification Technique of Resveratrol by High-Performance Liquid Chromatographic 
(HPLC) 
Following ICH Q2(R1) guidelines, we have demonstrated that our method meets the linearity 
criteria described in Table 1. The results show an excellent correlation between the areas of the 
chromatographic peak and the concentration of the analyte in the concentration range of 5–60 µg/mL. 
We also demonstrated that our method was selective, precise, accurate, and specific because all 
parameters met the established acceptance criteria (Table 1). 
In addition, we proved that although the resveratrol standard solution was stable for 96 h at 
room temperature, the sample test solution was only stable for 24 h, taking into account the 
established acceptance criteria (Table 1). 
2.2. Particle Size and Morphology  
After measuring the diameter of randomly selected fifty dry microparticles, as expected, the 
mean particle size was 1443.45 µm ± 126.11 µm, as we expected, as a result of using the ionotropic 
gelation method with a 25G needle to prepare the microparticles [9]. 
In ter s of orphology, the ne ly prepared icroparticles sho ed a spherical and unifor  
shape. o ever, ith dehydration the orphology beca e ore irregular, and particle size as 
reduced by about 500 µ , fro  2000 to 1500 µ  (Figure 2). 
 
Figure 2. Comparison of morphology and particle size between newly prepared (left) and dried 
(right) microparticles. 
2.3. Encapsulation Efficiency (EE) 
EE (%) determined by HPLC was 41.72% ± 1.92%. The low EE was most probably linked to the 
lipophility of resveratrol, which is why during gelation resveratrol could undergo diffusion from 
pectin-alginate mixture to gelation solution (CaCl2). Similar EE results were obtained by other authors 
using the same method for encapsulation of Cwp84 antigen [12]. 
2.4. Drug Release Study: Resveratrol Release from Microparticles 
As we can see in the Figure 3, in the first 2 h of the study, when particles were in contact with 
acidic medium, the percentage of resveratrol released from microparticles was less than 10%, meeting 
the criteria established in the European Pharmacopoeia monograph for gastro-resistant formulations 
Figure 2. Comparison of morphology and particle size between newly prepared (left) and dried
(right) microparticles.
2.3. Encapsulation Efficiency (EE)
EE (%) determined by HPLC was 41.72% ± 1.92%. The low EE was most probably linked to
the lipophility of resveratrol, which is why during gelation resveratrol could undergo diffusion from
pectin-alginate mixture to gelation solution (CaCl2). Similar EE results were obtained by other authors
using the same method for encapsulation of Cwp84 antigen [12].
2.4. Drug Release Study: Resveratrol Release from Microparticles
As we can see in the Figure 3, in the first 2 h of the study, when particles were in contact with acidic
medium, the percentage of resveratrol released from microparticles was less than 10%, meeting the
criteria established in the European Pharmacopoeia monograph for gastro-resistant formulations [13].
After 2 h, when the medium pH was changed from acidic to basic, the microspheres showed a faster
drug release rate, until reaching 70% of resveratrol total content in 24 h.
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Figure 3. Percentage of resveratrol release from microparticles. The microparticles were dispersed in
750 mL of an acid medium (pH 1.2) for 2 h, followed by a basic medium (pH 7.4). Values represent the
means (n = 6 for each test) ± the standard error.
2.5. In Vitro Bioactivity Study: Measurement of Triacylglycerol Content in Adipocytes
After incubation of adipocytes with resveratrol for 24 h, a reduction in triacylglycerol content
was observed for both concentrations used (1 and 10 µM). However, a dose-dependent effect was not
Molecules 2018, 23, 1886 5 of 10
observed. When comparing the effect of resveratrol released from the microparticles with that of free
resveratrol, no differences were found between both compounds (Figure 4).
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Figure 4. Triacylglycerol content in 3T3-L1 mature adipocytes after treatment with 1 and 10 µM free
resveratrol (RSV) and RSV released from microparticles (NP). Values are means ± SEM. Comparison
between each treatment with the control was analyzed by Student’s t-test. The asterisks represent
differences versus the control (* p < 0.05; ** p < 0.01).
3. Discussion
In the present study resveratrol loaded pectin/alginate blend gastro-resistant microparticles
were prepared as a new formulation to improve the oral bioavailability of resveratrol. Pectin resists
the enzymes present in the stomach and intestine, so it could protect resveratrol from metabolism
until it reaches the more distal parts of the intestine. Furthermore, alginate has properties which can
prolong the residence time of the microparticles in the administration site, and achieve a controlled
release, thanks to its bio/mucoadhesive properties [10]. The combination of these compounds is a
good strategy for the development of microparticles because they can be cross-linked with calcium
ions (Ca2+, divalent cations) obtaining Ca-pectinate-Ca-alginate networks. Therefore, the ionotropic
gelation method has been used for the preparation of pectin/alginate blend microparticles [9].
The resulting microparticles were subsequently coated with the enteric polymer Eudragit®FS-30D
to avoid completely the release of resveratrol until it reaches the distal intestinal tract, since this
methacrylic acid copolymer dissolves to pH 7 [11].
In order to demonstrate that we succeeded in producing gastro-resistant microparticles, we
carried out the dissolution assay described in the European Pharmacopoeia for delayed-release
dosage forms [14]. As the release study revealed, when particles were in contact with acid medium,
the percentage of resveratrol released from microparticles was less than 10%, meeting the criteria
established in the European Pharmacopoeia monograph for gastro-resistant formulations. While when
the pH of the medium was changed from acid to basic (pH 7.4), a faster dissolution rate which reached
70% of the total content in 24 h was observed. These results demonstrated that Eudragit FS-30D enteric
coating protected resveratrol loaded microparticles from acid pH, and therefore, that resveratrol will
be released into the distal portions of the intestinal tract after oral ingestion of miroparticles [15].
The advantages of microencapsulation to protect resveratrol and to increase its bioavailability
have been described in this manuscript, but when this strategy is used, it is necessary to check whether
it affects the biological activities of this compound. For his purpose, in the present study the effects of
encapsulated resveratrol and free resveratrol (used as a control) on triacylglycerol content in 3T3-L1
mature adipocytes was analyzed because, according to the results obtained in in vitro and in vivo
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studies [16–18], resveratrol has been proposed as a potential anti-obesity compound. It seems to mimic
the effects of energy restriction, thus leading to reduced body fat and improved insulin sensitivity [19].
Resveratrol supplements usually provide mg of this compound [20–22]. After absorption, intestinal
and hepatic metabolism, the amounts of resveratrol found in plasma and tissues are in the range of
1–2 µM [23,24]. Taking this is mind, the amounts of resveratrol used in the present study for adipocyte
culture were 1 and 10 µM.
Both forms of resveratrol, free and encapsulated, reduced triacylglycerol content at the two
doses used, and no differences were observed between them, meaning that in fact resveratrol was
not negatively affected by microencapsulation. In both cases the effect of 1 µM was greater than that
of 10 µM comparing to control. Although this seems surprising, the relationship between the dose
and the effectiveness is quite complex in polyphenol studies. In the case of resveratrol, this situation
(greater effects of lower doses than those of higher doses) has been already found in in vivo studies
by other authors. Thus, Cho et al., observed greater anti-obesity effect of resveratrol when mice were
treated with this phenolic compound at a dose of 0.005% in the diet than when they were treated at a
dose of 0.02% [25].
Taken as a whole, the present results show that pectin/alginate gastro-resistant microparticles
protect resveratrol from acid pH, allowing the phenolic compound to be released into the distal
portions of the intestinal tract after oral ingestion of miroparticles. In addition, resveratrol remains
active after the encapsulation process. Consequently, this type of microencapsulation could be a useful
strategy in the development of dietary supplements or functional foods that may be beneficial for the
prevention or treatment of obesity.
4. Materials and Methods
4.1. Materials
Pectin (from apple) (CAS Number: 9000-69-5), alginate (from Brown algae) (CAS Number:
9005-38-3), calcium chloride (CAS Number: 10043-52-4), and pectinase (from Aspergillus aculeatus)
(MDL number: MFCD00131809) were purchased from Sigma-Aldrich Química S.A (Madrid, Spain).
Trans-resveratrol (Resveratrol 95% (HPLC) from Polygonum cuspidatum) was supplied by Monteloeder
(Alicante, Spain). Eudragit FS-30D was obtained from Evonik (Essen, Alemania). Triethyl citrate (TEC)
(CAS Number: 77-93-0) was donated by Morflex. Methanol HPLC grade (CAS Number: 67-56-1),
Formic acid (98–100%, reagent grade) (CAS Number: 64-18-6), HCl 35% w/w (CAS Number: 7647-01-0),
NaOH (CAS Number: 1310-73-2) and tri-Sodium phosphate monohydrate were purchased from
Scharlau (Barcelona, Spain). Dulbecco´s modified Eagle´s medium (CAS Number: 103130-21) was
supplied by GIBCO (BRL Life Technologies, Grand Island, NY, USA). Triacylglcyerols (TG) were
determined by Infinity Triglycerides reagent (Thermo Electron Corporation, Rockford, IL, USA) and
protein concentrations of cell extracts were measured with BCA reagent (Thermo Scientific, Rockford,
IL, USA).
4.2. Preparation of Microparticles
Microparticles were prepared using the ionotropic gelation method [9]. Firstly, pectin (2%, (w/v);
2 g in 100 mL) and alginate (1%, (w/v); 1 g in 100 mL) were dissolved in deionized water and resveratrol
(10%, w/w; 0.3 g) was dispersed in it. This mixture was then added dropwise through a needle of 25G
on a gently agitated CaCl2 dissolution (5%, (w/v); 10 g in 200 mL), using a peristaltic pump (ecoline,
ISMATEC, 0.4 mL/min). Subsequently, microparticles were obtained by the gelation of the pectin and
the alginate and held in magnetic stirring for 3 h. The microparticles were then separated; washed
with distilled water; and dried on a fluidized bed, Mini Glatt 4® (for 10 min at 70 ◦C).
The dried microparticles were coated with a Eudragit® FS-30D (20%, (w/w)) and TEC (1.5%,
(v/w)) solution, on the fluidized bed, Glatt® (70 ◦C, 0.6–0.7 bar). The coating solution was atomized
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into microparticles using a peristaltic pump (0.3 mL/min) until the desired coating thicknesses were
achieved, with an increase in weight of 20%.
Empty microparticles were prepared by the same procedure, but without adding resveratrol to
the pectin and alginate mixture.
4.3. Development and Validation of an HPLC Method for the Quantification of Resveratrol
Quantitative high-performance liquid chromatographic (HPLC) analysis was performed on a
Waters HPLC system (Waters Corporation, Milford, MA, USA) equipped with a binary HPLC pump
(Waters 1525), a dual λ Absorbance UV-visible detector (Waters 2487), a column oven (Waters Column
Heater Module), and an auto sampler (Waters 717 plus Autosampler) controlled by software (Empower
3 Software), which was used for data analysis and processing.
An HPLC method was developed for the quantification of resveratrol in the microparticles. It was
carried out on a XBridge column (4.6 × 75 mm, C18 2.5 µm) with column oven temperature of 35 ◦C
using a gradient elution system consisting of MeOH and Formic acid 0.1%. The proportion of Formic
acid/MeOH in the gradient was 50:50, 50:50, 10:90, 10:90, 50:50, and 50:50, at 0, 0.5, 2, 4.5, 4.51, and
8.5 minutes, respectively. The retention time of trans- and cis-resveratrol were 2.42 min and 3.84 min,
respectively, with a flow rate of 0.7 mL/min. The analysis was carried out at 305 nm and 285 nm
wavelength for trans- and cis-resveratrol, respectively, with a run time of 8.5 min.
The method was validated according to the ICH Q2(R1) guideline [13] in terms of linearity in the
concentration range of 5–60 µg/mL, selectivity, precision, accuracy, specificity and stability. With the
results obtained in each of the trials, it was seen whether the different parameters met the established
acceptance criteria, described in Table 1.
4.4. Characterization of Microparticles
4.4.1. Particle Size
The size of the dry microparticles was measured by an optical microscope (Nikon ECLIPSE
TE2000-S), set at 4X objective. Fifty microparticles were randomly selected, and the diameter of each
one was measured with the help of the scale of the Eclipse Net software, after capturing the images
through a digital camera (Nikon Digital Sight DS-U1) connected with the microscope. The average
size of the microparticles was expressed as the mean diameter (µm) ± standard deviation (SD).
4.4.2. Encapsulation Efficiency (EE%)
Resveratrol EE was determined by a direct method. Briefly, 10 mg of microparticles was added
to a topaz flask of 10 mL with a mix of MeOH–H2O–Formic acid (45:55:0.1) and pectinase (1%, w/v).
The mixture was left in magnetic stirring until the dissolution of the particles, in order to completely
extract the resveratrol from microparticles. The concentration of resveratrol in the flask was determined
by HPLC. The experiment was performed in triplicate. EE was expressed as the actual resveratrol
mass percentage, compared with the total mass of resveratrol added initially.
4.4.3. Dissolution Assay
The assay was conducted as described in the European Pharmacopoeia for delayed-release dosage
forms under Apparatus 1 (Sotax dissolution tester), using the specified media at 37 ◦C and 50 rpm [14].
Firstly, the test was performed in an acid medium (HCl, 0.1 N). For this, seven vessels of the
apparatus were filled with 750 mL of 0.1 N hydrochloric acid, and microparticles were placed in
the baskets (empty microparticles in the first vessel, and resveratrol loaded in the rest). After 2 h of
operation, an aliquot of each vessel was withdrawn and replaced with the same volume of medium.
Immediately, 250 mL of tri-Sodium phosphate monohydrate was added to the vessels and the pH
was adjusted to 7.4 with NaOH 2 N, to continue with the test in a basic medium. At different times
(1 h, 2.5 h, 5 h, and 24 h) aliquots were withdrawn and replaced with the same volume of medium.
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All aliquots were analyzed by HPLC to obtain the concentration of resveratrol, and results were
expressed as cumulative percentage of resveratrol released from the microparticles at a given time,
against the initial resveratrol loading in the microparticle sample.
4.5. In Vitro Bioactivity Assay
4.5.1. Experimental Design
The 3T3-L1 pre-adipocytes, supplied by American Type Culture Collection (Manassas, VA, USA),
were cultured in DMEM containing 10% foetal calf serum (FCS). Two days after confluence (day
0), the cells were stimulated to differentiation with DMEM containing 10% v/v FCS, 10 µg/mL
insulin, 0.5 mM isobutylmethylxanthine (IBMX), and 1 µM dexamethasone for two days. On day
4, the differentiation medium was replaced by FBS/DMEM medium (10%) containing 0.2 µg/mL
insulin. This medium was changed every two days until cells were harvested. All media contained
1% v/v Penicillin/Streptomycin (10,000 U/mL), and the media for differentiation and maturation
contained 1% (v/v) of Biotin and Panthothenic Acid. Cells were maintained at 37 ◦C in a humidified
5% CO2 atmosphere.
4.5.2. Cell Treatment
For the treatment of mature adipocytes, cells grown in six-well plates were incubated with free
resveratrol and resveratrol released from microparticles, at 1 and 10 µM (diluted in 95% ethanol, final
ethanol concentration in the medium 0.1%) on day 12 after differentiation because on that day, >90%
of cells had matured, with visible lipid droplets. After 24 h, supernatant was removed and cells were
used for triglyceride (TG) determination. This experiment was repeated three times.
4.5.3. Measurement of Triacylglycerol Content in Adipocytes
Mature adipocytes were washed extensively with phosphate-buffered saline (PBS) and incubated
three times with 800 µL of hexane/isopropanol (2:1). The total volume was then evaporated by
nitrogen gas and the pellet was resuspended in 200 µL Tritón X-100 in 1% distilled water. Afterwards,
TG were disrupted by sonication and the content was measured by a commercial kit. For protein
determinations, cells were lysed in 0.3 N NaOH, 0.1% SDS. Protein measurements were performed
using the BCA reagent. TG content results were obtained as mmol glycerol/mg protein and were
converted to arbitrary units.
4.5.4. Statistical Analysis
Results are presented as mean + standard error of the mean. Statistical analysis was performed
using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Statistical analysis was determined by unpaired Student’s
unpaired t-test (two-tailed). Statistical significance was set-up at the p < 0.05 level.
5. Conclusions
Taking into account the results obtained, it may be concluded that the developed gastro-resistant
microparticles can represent an appropriate strategy for the inclusion of resveratrol in dietary
supplements and functional foods with potential beneficial effects in the prevention or treatment
of obesity.
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